share_log

Apellis Pharmaceuticals | SC 13G: Statement of acquisition of beneficial ownership by individuals-T. Rowe Price Investment Management, Inc.(5.3%)

SEC announcement ·  Feb 14 14:31
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more